Science 37 Holdings Inc represents values centered around innovation, collaboration, and patient-centricity. By using technology-driven solutions, Science 37 aims to advance clinical research and make healthcare more accessible. The company's corporate philosophy focuses on promoting inclusivity, transparency, and scientific integrity in the development of novel therapeutics. Science 37 believes in empowering patients by bringing clinical trials directly to them through remote and virtual trials. By leveraging their proprietary platform, NORA®, Science 37 enables convenient participation and efficient data collection, revolutionizing the way clinical trials are conducted. Overall, Science 37 Holdings Inc strives to improve healthcare outcomes and revolutionize the clinical research landscape.

Science 37 Holdings Inc is primarily present in the United States.

Some significant milestones achieved by Science 37 Holdings Inc include building a global network of clinical research sites, pioneering the use of decentralized clinical trials, and attracting partnerships with leading pharmaceutical companies. The company has successfully conducted numerous clinical trials across therapeutic areas, contributing to the advancement of medical research. Science 37 Holdings Inc has also received recognition and awards for its innovative approach to clinical trials and its commitment to transforming the traditional research model. With its continuous growth and impact, Science 37 Holdings Inc remains a prominent player in the field of decentralized clinical trials and pharmaceutical research.

Science 37 Holdings Inc. is a healthcare technology company specializing in decentralized clinical trials. Founded in 2014, the company offers a unique platform that enables virtual participation in clinical research, thereby increasing patient access and engagement. Science 37 combines advanced telemedicine technology, data analytics, and patient-centric services to streamline the clinical trial process and improve patient outcomes. With a focus on innovative solutions, Science 37 has emerged as a leader in the digital health landscape, empowering patients and researchers to collaborate seamlessly from any location. Through its pioneering approach, Science 37 aims to revolutionize clinical research and transform the future of medicine.

The main competitors of Science 37 Holdings Inc in the market include other contract research organizations (CROs) like IQVIA Holdings Inc, PRA Health Sciences Inc, and Medpace Holdings Inc. These companies also provide clinical research services and aim to accelerate the drug development process. However, Science 37 differentiates itself through its unique decentralized clinical trial model, which leverages telemedicine and mobile technology to conduct remote patient visits, enhancing convenience and participation. Despite facing competition in its industry, Science 37's innovative approach positions it as a leading player in revolutionizing clinical trials.

Science 37 Holdings Inc is primarily active in the healthcare and clinical research industries.

The business model of Science 37 Holdings Inc is centered around providing technology-enabled clinical research services. They aim to transform the traditional clinical trial process by utilizing a decentralized model that allows patients to participate in trials from the comfort of their own homes. Science 37 leverages a cloud-based platform to connect patients, investigators, and clinical research teams, enabling seamless collaboration and data collection. Their innovative approach not only increases accessibility and diversity in clinical trials but also accelerates the development of new medical treatments. With their emphasis on virtual clinical trials, Science 37 Holdings Inc aims to revolutionize the way research is conducted in the healthcare industry.

Science 37 Holdings KGV ir -1,62.

Science 37 Holdings KUV ir 10,40.

AlleAktien kvalitātes vērtējums Science 37 Holdings ir 3/10.

gaidāmā Science 37 Holdings apgrozījums ir 64,07 milj. USD.

gaidāmā Science 37 Holdings peļņa ir -411,64 milj. USD.

Science 37 Holdings Inc is a company that is revolutionizing global clinical research. The company has developed an innovative business model that combines traditional methods of clinical trials with digital technology to provide a unique and improved clinical research experience. The company offers a range of products and services, including a cloud-based platform called NORA that allows for seamless conduct of clinical trials. The platform also provides a secure environment for collaboration between researchers, physicians, patients, and sponsors. Another product is the mobile clinical research associate (MCRA), which assists research staff in recruiting participants, conducting site checks, and transmitting real-time study protocols to study operators. The company also offers a comprehensive service platform that conducts virtual clinical trials (VCT). This means that clinical research studies can be conducted entirely remotely, without the need for participants or researchers to be physically present. This allows patients to participate in studies that would otherwise be inaccessible due to geographical and time constraints. It also reduces the costs and efforts associated with conducting trials and facilitates data analysis and monitoring. In addition, Science 37 Holdings Inc also has an extensive patient acquisition and retention division that creates an excellent experience for patients and their families. The company utilizes innovative digital communication tools to identify potential participants and engage them throughout the study process. Science 37 Holdings Inc. works closely with leading pharmaceutical and biotech companies to ensure rapid and effective translation of study results from research to practice. By involving patients in the process, the company becomes a key player in the development of evidence-based drugs and therapies. Overall, Science 37 Holdings Inc has taken a unique market position by harnessing the potential of digital technology in clinical research to streamline processes, improve patient retention, alleviate the burden on staff, and accelerate the dissemination of research findings. This company's innovation has the potential to contribute to significant advancements in medicine in the future.

Science 37 Holdings izmaksā dividendes 0 USD, kas tiek izmaksātas reizes gadā.

Dividendes pašlaik nevar aprēķināt Science 37 Holdings vai uzņēmums nedod dividendes.

Science 37 Holdings ISIN ir US8086441081.

Science 37 Holdings simbols ir SNCE.

Pēdējo 12 mēnešu laikā Science 37 Holdings maksāja dividendes apmērā. Tas atbilst aptuveni dividendes ražībai. Nākamajos 12 mēnešos Science 37 Holdings plāno maksāt dividendes 0 USD apmērā.

Science 37 Holdings pašreizējā dividendu rentabilitāte ir .

Science 37 Holdings maksā dividendes ceturksnī. Tās tiek izmaksātas mēnešos .

Science 37 Holdings pēdējo 0 gadu laikā katru gadu izmaksāja dividendes.

Nākamajiem 12 mēnešiem tiek prognozētas dividendes apmērā 0 USD. Tas atbilst dividendes ražībai 0 %.

Science 37 Holdings tiek piešķirts nozarei "Veselība".

Lai saņemtu pēdējo dividendu Science 37 Holdings apmērā 0 USD, kas tika izmaksāta 31.08.2024., tev akcija bija jāpatur depozītā līdz Ekss dienai, kas bija 31.08.2024..

Pēdējās dividendes izmaksa notika 31.08.2024..

Gadā 2023, Science 37 Holdings izmaksāja 0 USD dividendes.

Science 37 Holdings dividendes tiek izmaksātas USD.